반응식
Cl.[Cl:2][C:3]1[C:4]([N:9]2[CH2:14][CH2:13][NH:12][CH2:11][CH2:10]2)=[N:5][CH:6]=[CH:7][CH:8]=1.Cl[C:16]1[NH:20][C:19]2[CH:21]=[C:22]([C:26]([F:29])([F:28])[F:27])[CH:23]=[C:24]([Cl:25])[C:18]=2[N:17]=1.C(N(CC)C(C)C)(C)C>>[Cl:25][C:24]1[C:18]2[N:17]=[C:16]([N:12]3[CH2:11][CH2:10][N:9]([C:4]4[C:3]([Cl:2])=[CH:8][CH:7]=[CH:6][N:5]=4)[CH2:14][CH2:13]3)[NH:20][C:19]=2[CH:21]=[C:22]([C:26]([F:29])([F:28])[F:27])[CH:23]=1참가 물질
4
실험 절차
The reaction of 1-(3-chloropyridin-2-yl)piperazine hydrochloride (99 mg, 0.5 mmol, Example 3b) and 2,4-dichloro-6-trifluoromethyl-1H-benzoimidazole (76 mg, 0.3 mmol, Example 5b) and N,N-diisopropylethylamine (0.17 mL, 1 mmol, Aldrich) under the conditions of Example 3c afforded the title compound as a white amorphous solid. MS (ESI, pos. ion) m/z: 416 (M+1).
출처 및 근거
- ORD 기록
- ord-251bf48d86f74d24bb1882a57b49aec7
- 출처 데이터셋
- uspto-grants-2009_09
- 특허 번호
- US07582761B2
연결된 노트
불러오는 중…